Kala Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary

KALA BIO

14/05/2024 23:08

* KALA BIO Inc  KALA.OQ  reported a quarterly adjusted loss
of
$4.19​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of
$-6.99.  The mean expectation of three analysts for the quarter
was for a loss of $2.89 per share. Wall Street expected
results to range from $-3.14 to $-2.64 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * KALA BIO Inc's reported EPS for the quarter was a loss of
$4.19​.
    * The company reported a quarterly loss of $11.81 million.
    * KALA BIO Inc shares had fallen by 14.5% this quarter and
lost 2.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 20.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "strong buy"

Wall Street's median 12-month price target for KALA BIO Inc is
$21.00 
This summary was machine generated from LSEG data May 14 at
10:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -2.89          -4.19          Missed
 Dec. 31 2023      -3.62          -3.18          Beat
 Sep. 30 2023      -2.15          -3.41          Missed
 Jun. 30 2023      -3.19          -4.36          Missed